Subject(s)
Fanconi Anemia/complications , Sweet Syndrome/etiology , Adolescent , Biopsy , Child , Child, Preschool , Disease Progression , Humans , Skin/pathologyABSTRACT
A20, a negative regulator of NF-κB, has been implicated as a tumor suppressor gene in multiple types of B-cell lymphoma. AIDS-related lymphomas (ARLs) are high-grade B-cell lymphomas that are frequently associated with EBV infection. We examined a panel of ARLs for A20 alterations. FISH showed A20 deletion in 6 of 33 cases (18%). A20 mutations were found in 3 of 19 cases (16%), including 2 cases with deletions of the comple-mentary allele. Immunohistochemistry showed the absence of A20 protein in 7 of 55 samples (13%). In contrast to reports in Hodgkin lymphoma in which EBV infection and A20 alteration are mutually exclusive, A20 inactivation was observed in both EBV(+) and EBV(-) cases. The EBV latent membrane protein 1, which activates NF-κB, was not expressed in 12 of 13 cases with A20 loss. In ARLs loss of A20 may be an alternative mechanism of NF-κB activation in the absence of latent membrane protein 1 expression.
Subject(s)
Epstein-Barr Virus Infections/genetics , Intracellular Signaling Peptides and Proteins/genetics , Lymphoma, AIDS-Related/genetics , Lymphoma, AIDS-Related/virology , Mutation , Nuclear Proteins/genetics , DNA Mutational Analysis , DNA-Binding Proteins , Epstein-Barr Virus Infections/metabolism , Gene Deletion , Gene Silencing , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Intracellular Signaling Peptides and Proteins/metabolism , Lymphoma, AIDS-Related/metabolism , NF-kappa B/metabolism , Nuclear Proteins/antagonists & inhibitors , Nuclear Proteins/metabolism , Tumor Necrosis Factor alpha-Induced Protein 3 , Viral Matrix Proteins/metabolismABSTRACT
Monoclonal antibodies are among the most important class of drugs introduced into the therapeutic armamentarium since the introduction of antimicrobials in the 1930s. The first therapeutic monoclonal antibody, the anti T-cell monoclonal antibody OKT4, was licensed in 1986. Since then, 18 additional antibodies have been licensed in the US, with many more in the pipeline. Before 1986, many monoclonal antibodies were available for laboratory studies, notably to identify specific cells in the blood and tissues. This is best illustrated by the cluster designation (CD) system for antigens present on hematopoietic cells, now numbering over 200.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal/adverse effects , Antigen-Antibody Complex , Antigens, Surface/immunology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Cytokines/immunology , Forecasting , Humans , Neoplasms/drug therapy , Neoplasms/immunology , Rheumatic Diseases/drug therapy , Rheumatic Diseases/immunology , United StatesSubject(s)
Antibodies, Monoclonal/therapeutic use , Hematologic Diseases/drug therapy , Immunologic Factors/therapeutic use , Adolescent , Adult , Anemia, Hemolytic, Autoimmune/drug therapy , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal, Murine-Derived , B-Lymphocytes/drug effects , B-Lymphocytes/metabolism , Child , Child, Preschool , Drug Administration Schedule , Drug Evaluation , Female , Hematologic Diseases/immunology , Hemophilia A/drug therapy , Humans , Immunologic Factors/pharmacokinetics , Infant , Infusions, Intravenous , Leukemia/drug therapy , Lymphoma/drug therapy , Lymphoproliferative Disorders/drug therapy , Male , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Rituximab , Treatment OutcomeABSTRACT
The diagnosis of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) requires a prospectively determined association between group A beta-hemolytic streptococcal (GABHS) infection and obsessive-compulsive disorder (OCD) or tic disorder. Screening for GABHS infection imposes a significant burden on both patient and clinician. To heighten the index of suspicion for PANDAS, it would be useful to know if parent-reported upper respiratory infection (URI) is associated with PANDAS symptoms or associated characteristics. Eighty-three consecutive, clinically referred patients aged 6 to 17 years with a primary diagnosis of OCD and their primary caregivers were asked about URI signs and symptoms at the time of OCD onset, PANDAS symptoms, OCD and tic symptoms, comorbidity, and putative PANDAS risk factors. Specific inquiry regarding URI symptoms proved more informative than general inquiry. In the URI present versus URI absent group, more patients experienced a sudden rather than insidious onset of symptoms. Additionally, more patients with a URI plus sudden onset exhibited a comorbid tic disorder. Until validated biomarkers permit retrospective diagnosis, a history that OCD began around the time of a URI should clue the clinician to look prospectively for PANDAS. Additional research is required to define the boundaries of PANDAS and to develop psychometrically reliable and valid diagnostic strategies.
